P298 - BODY COMPOSITION EFFECTS OF LOW DOSE GLUTAMINE AND VITAMIN SUPPLEMENT WITH AN ANTI-INFLAMMATORY DIET IN EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY PATIENTS.

P298

BODY COMPOSITION EFFECTS OF LOW DOSE GLUTAMINE AND VITAMIN SUPPLEMENT WITH AN ANTI-INFLAMMATORY DIET IN EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY PATIENTS.

C. Flores^1,*, E. Diaz Quiñones¹

¹Immunonutrition, Private Practice., Huixquilucan, Mexico

Rationale: Glutamine supplementation in cancer is controversial due to its role in tumor growth, but it's essential for anti-tumoral immune response. 

Methods: The aim of this pilot study was to determine if we could achieve an improvement in body composition in patients with early breast cancer by taking a low dose Glutamine (Glu), vitamin D, vitamin B6 and Zinc supplement paired with an anti-inflammatory diet.  We compared body composition results in early stage breast cancer patients taking the supplement under an anti-inflammatory normocaloric diet in a 3 month followup. Descriptive statistics were made and then T value for paired samples was performed. Statistics were analyzed using SPSS 30 software. This protocol had bioethics committee clearing.

Results: We studied the results of 55 women diagnosed with early breast cancer taking a low dose glutamine, vitamin D, vitamin B6 and zinc supplement on an anti-inflammatory normocaloric diet, all of them were on adjuvant chemotherapy. Median age was 44 years. When comparing Body fat percentage pre and post-intevention T value was 0.723 with a P<0.001. Comparing Muscle mass in kg pre and post-intervention T value was 0.959 with a P<0.001. Comparing body weight pre and post-intervention T value was 0.991 with a with a P<0.001. Comparing BMI pre and post-intervention T value was 0.955 with a with a P<0.001.

Conclusion: This exploratory study shows a tendency for improvement in body composition with our nutritional intervention, even though they were taking adjuvant chemotherapy, statistical significance was obtained. Further research needs to be done in future studies.

References: Nan D, Yao W, Huang L, Liu R, Chen X, Xia W, Sheng H, Zhang H, Liang X, Lu Y. Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets. Cell Commun Signal. 2025 Jan 24;23(1):45. 

Disclosure of Interest: C. Flores Speakers Bureau of: Advisory board consultant, E. Diaz Quiñones: None declared